The Median Eminence, A New Oligodendrogenic Niche in the Adult Mouse Brain

por Zilkha-Falb, Rina, Kaushansky, Nathali, Ben-Nun, Avraham
Publicado 2020

Post-CNS-inflammation expression of CXCL12 promotes the endogenous myelin/neuronal repair capacity following spontaneous recovery from multiple sclerosis-like disease

por Zilkha-Falb, Rina, Kaushansky, Nathali, Kawakami, Naoto, Ben-Nun, Avraham
Publicado 2016

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study

por Harari, Gil, Gurevich, Michael, Dolev, Mark, Zilkha Falb, Rina, Achiron, Anat
Publicado 2023

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice

por Zilkha-Falb, Rina, Rachutin-Zalogin, Tatyana, Cleaver, Lakota, Gurevich, Michael, Achiron, Anat
Publicado 2020

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

por Achiron, Anat, Gurevich, Michael, Falb, Rina, Dreyer-Alster, Sapir, Sonis, Polina, Mandel, Mathilda
Publicado 2021

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis

por Gurevich, Michael, Miron, Gadi, Falb, Rina Zilkha, Magalashvili, David, Dolev, Mark, Stern, Yael, Achiron, Anat
Publicado 2015

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients

por Menascu, Shay, Khavkin, Yulia, Zilkha‐Falb, Rina, Dolev, Mark, Magalashvili, David, Achiron, Anat, Gurevich, Michael
Publicado 2020

‘Multi-Epitope-Targeted’ Immune-Specific Therapy for a Multiple Sclerosis-Like Disease via Engineered Multi-Epitope Protein Is Superior to Peptides

por Kaushansky, Nathali, Kerlero de Rosbo, Nicole, Zilkha-Falb, Rina, Yosef-Hemo, Reut, Cohen, Lydia, Ben-Nun, Avraham
Publicado 2011

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents

por Gurevich, Michael, Zilkha‐Falb, Rina, Sonis, Polina, Magalashvili, David, Dolev, Mark, Mandel, Mathilda, Menascu, Shay, Achiron, Anat
Publicado 2022

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients

por Gurevich, Michael, Zilkha-Falb, Rina, Sonis, Polina, Magalashvili, David, Menascu, Shay, Flechter, Shlomo, Dolev, Mark, Mandel, Mathilda, Achiron, Anat
Publicado 2022

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Publicado 2021

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Flechter, Shlomo, Falb, Rina, Gurevich, Michael
Publicado 2021

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

por Achiron, Anat, Mandel, Mathilda, Gurevich, Michael, Dreyer-Alster, Sapir, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Harari, Gil, Flechter, Shlomo, Falb, Rina
Publicado 2022

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Magalashvili, David, Menascu, Shay, Warszawer, Yehuda, Dolev, Mark, Didikin, Maria, Harari, Gil, Sonis, Polina, Falb, Rina, Gurevich, Michael
Publicado 2023

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

por Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
Publicado 2021

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

por Achiron, Anat, Dolev, Mark, Menascu, Shay, Zohar, Daniela-Noa, Dreyer-Alster, Sapir, Miron, Shmuel, Shirbint, Emanuel, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Polliack, Michael, Falb, Rina, Gurevich, Michael
Publicado 2021

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

por Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Publicado 2022